Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

Only Treatment Option to Target Underlying Cause of Serious Lupus Complication, Aiming to Preserve Kidney Function NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from Genentech...